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ABSTRACT
Several studies have linked overexpression of the LIM and SH3 domain protein 
1 (LASP1) to progression of breast, colon, liver, and bladder cancer. However, 
its expression pattern and role in human prostate cancer (PCa) remained largely 
undefined.
Analysis of published microarray data revealed a significant overexpression of 
LASP1 in PCa metastases compared to parental primary tumors and normal prostate 
epithelial cells. Subsequent gene-set enrichment analysis comparing LASP1-high 
and -low PCa identified an association of LASP1 with genes involved in locomotory 
behavior and chemokine signaling. These bioinformatic predictions were confirmed 
in vitro as the inducible short hairpin RNA-mediated LASP1 knockdown impaired 
migration and proliferation in LNCaP prostate cancer cells. 
By immunohistochemical staining and semi-quantitative image analysis of 
whole tissue sections we found an enhanced expression of LASP1 in primary PCa 
and lymph node metastases over benign prostatic hyperplasia. Strong cytosolic and 
nuclear LASP1 immunoreactivity correlated with PSA progression. Conversely, qRT-
PCR analyses for mir-203, which is a known translational suppressor of LASP1 in 
matched RNA samples revealed an inverse correlation of LASP1 protein and mir-203 
expression. Collectively, our results suggest that loss of mir-203 expression and thus 
uncontrolled LASP1 overexpression might drive progression of PCa.
INTRODUCTION
Prostate cancer (PCa) is the most frequent cancer 
of men in the western world [1]. Although many PCa 
are rather indolent tumors and remain clinically stable 
for many years or even decades and do not require any 
treatment, more aggressive PCa subtypes metastasize early 
and are associated with dismal outcome [2-4]. In 1986, 
introduction of prostate specific antigen (PSA) testing 
has significantly improved early diagnosis of PCa [5]. 
However, although high serum PSA levels may correlate 
with PCa aggressiveness [6], PSA testing has caused a 
stage shift to less aggressive PCa. Over-detection and 
over-treatment are the main drawbacks of PSA-testing 
and unintentionally affect patients’ quality of life [7]. 
Consequently, there is an urgent need for prognostic 
biomarkers to discriminate indolent from highly 
aggressive PCa in order to better guide an individual 
patient´s treatment.
Recently, Erho et al. [8] developed and validated a 
PCa genomic classifier set with 22 markers that predicts 
metastatic progression better than clinicopathologic 
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variables. The LIM and SH3 protein 1 (LASP1) is one of 
these markers. 
LASP1 is a nucleo-cytosolic shuttling protein 
involved in migration, adhesion, proliferation and cell 
cycle progression of many cancers [9]. LASP1 was 
initially identified from a cDNA library of breast cancer 
metastases and the corresponding protein is overexpressed 
in more than 50% of all breast cancers [10-12]. Besides its 
function as a structural scaffolding protein at sites of actin 
assembly such as invadopodia and membrane ruffles [13], 
LASP1 likely acts as a signaling molecule transducing 
information from the cytoplasm into the nucleus [14]. 
LASP1 is expressed in virtually all normal tissues [9], 
but overexpressed in many cancer entities such as the 
aggressive pediatric brain tumor medulloblastoma [15] as 
well as breast [12], ovarian [16] and colorectal carcinoma 
[17]. Moreover, LASP1 overexpression correlates with 
adverse outcome in these cancer entities suggesting an 
oncogenic function of LASP1 [12, 15, 17]. Expression 
of LASP1 is regulated i) by tumor suppressor p53 on the 
genomic level as shown for hepatocellular carcinoma 
[18] and ii) on the protein level by microRNA mir-203 as 
described for esophageal squamous cell carcinoma [19], 
breast cancer [20], and PCa [21, 22].
Here, we investigated the LASP1 expression pattern 
in a large series of surgically treated high-risk PCa samples 
(n=161) and correlated LASP1 protein levels with mir-203 
expression levels in a subset of the same tumors (n=138). 
In addition, we investigated the effect of RNA interference 
mediated LASP1 knockdown in a metastatic PCa cell line.
Our data demonstrate for the first time that LASP1 
is overexpressed in a subset of high-risk PCa and that this 
expression correlates with PSA progression. qRT-PCR 
revealed a correlation between high LASP1 protein levels 
and reduced mir-203 expression in the PCa tissue samples. 
Cell culture experiments underline the more proliferative 
and migratory PCa phenotype in high LASP1 expressing 
cells. 
These data might represent a first step toward 
characterizing LASP1 as a promising novel candidate 
biomarker to discriminate indolent from aggressive PCa.
RESULTS
LASP1 mRNA expression is increased in prostate 
cancer metastases and is associated with pathways 
involved in cell migration
As LASP1 is overexpressed in several cancer 
entities [15-17], we assessed the LASP1 mRNA 
expression pattern in publicly available microarray 
datasets. Specifically, microarray data of primary PCa 
(n=61) and PCa metastases (n=25) were compared with 
normal prostate tissue (n=18). As displayed in Figure 1A, 
Figure 1: LASP1 mRNA expression is increased in prostate cancer metastases and is associated with pathways involved 
in cell migration A: LASP1 is significantly overexpressed in PCa metastases compared to parental primary tumors and 
normal prostate epithelial cells (p=0.028; Student´s t test metastasis versus normal and primary). B: Gene expression signatures 
in the top 10 LASP1-high versus top 10 LASP1-low PCa samples by gene-set enrichment analysis (GSEA). C: GSEA analysis of the PCa 
microarray data, showing significant enrichment of genes involved in locomotory behaviour and chemokine signaling. 
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LASP1 is significantly (p=0.028) overexpressed in PCa 
metastases compared to normal tissues and the primary 
tumor.
To investigate LASP1 correlated pathways, we 
analyzed a large PCa microarray study (n=154) for 
LASP1 expression. As displayed in Figure 1B, LASP1 is 
moderately expressed in most PCa samples but appears 
to be overexpressed in about 15% of PCa samples 
(designated as LASP1-high). Subsequently, we compared 
the gene expression signatures in the top 10 LASP1-high 
versus top 10 LASP1-low PCa samples (Figure 1B and 
Supplemental Table 1) by gene-set enrichment analysis 
Figure 2: LASP1 protein expression is elevated in metastatic prostate cancer A: Representative immunostaining of BPH: 
most hyperplastic cells are LASP1 negative, both, for cytosol and nucleus (green arrows). Smooth muscle cells of blood vessels are 
positive for LASP1 (blue arrow). B: Representative PCa immunostaining (Gleason 8): most cells display positive LASP1 staining, both, 
for cytosol (IRS 4) and nuclei (red arrows). C and D: Prostate cancer (Gleason 8) with corresponding LNM, respectively: in PCa most 
cells are weak positive for cytosolic LASP1 staining (IRS 1) (green arrows). Few cells show additional positive nuclear LASP1 staining 
(red arrow). Compared to the primary tumor shown in C, in LNM (D) the overall cytosolic LASP1 staining (IRS 4) (green arrows) and the 
amount of cells with additional LASP1 positive nuclei (red arrows) are increased. LASP1 positive lymphocytes are marked with a black 
asterisk. (DAB, brown, magnification x40)
Table 1: Patient characteristics (n=161)
Parameters Median
Age at surgery, years (range) 65.9 (43-81)
Mean follow-up, months (range) 47.14 (1-105)
Nuclear LASP1 positivity 56 (34.78%)
LASP1-IRS positivity 39 (24.22%)
Clinical failure/ clinical recurrence 19 (11.80%)
Mean preoperative PSA (ng/ml) (range) 48.07 (20-160)
Death for any reason 22 (13.66%)
Cancer related death (CRD) 10 (6.21%)
Cancer specific survival, months (range) 43.7 (14-63)
Biochemical progression / PSA progression 41 (25.47%)
Average time to PSA progression, months(range) 22.8 (1-54)
Average time to clinical progression, months (range) 26.79 (3-89)
Gleason score
6 3 (1.86%)
7 49 (30.43%)
8 52 (32.3%)
9 43 (26.71%)
10 14 (8.7%)
Pathological tumor stage
pT2 23 (14.29%)
pT3a 44 (27.33%)
pT3b 67 (41.61%)
pT4 27 (16.77%)
Lymph node positive 59 (36.65%)
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(GSEA). GSEA revealed that LASP1 overexpression in 
clinical PCa samples is strongly correlated (p<0.001) with 
gene signatures involved in locomotory behaviour and 
chemokine signaling (Figure 1C). Collectively, these data 
indicate that LASP1 overexpression is associated with a 
more aggressive PCa phenotype.
LASP1 protein expression is elevated in metastatic 
prostate cancer 
To validate our findings on LASP1 overexpression in 
a subset of PCa samples on protein level, we investigated 
the LASP1 protein expression pattern by immuno-
histochemistry (IHC) in specimens from 15 benign 
prostatic hyperplasias (BPH), 161 high-risk PCa derived 
from patients with pre-treatment PSA >20 ng/ml who 
underwent radical prostatectomy, and 17 corresponding 
lymph node metastases (LNM). Representative samples 
for the observed LASP1 immunoreactivity are shown in 
Figure 2. Analysis of the Immune Reactive Scores (IRS) 
revealed that the median expression of LASP1 increases 
from BPH (IRS 2.0 ± 1) to PCa (IRS 3.0 ± 2) and LNM 
(IRS 4.0 ± 1). Interestingly, only PCa and LNM showed 
very high IRS values up to 12 while in BPH, the IRS 
maximum is 6. Accordingly, a low cytosolic LASP1 
expression correlated with negative/low nuclear staining 
and a high cytosolic expression with high nuclear LASP1 
immunoreactivity (p=0.0001, Table 2). These analyses 
confirmed an increase of LASP1 protein levels in 
metastatic high-risk PCa.
Silencing of LASP1 impairs proliferation and 
migration of prostate cancer cells in vitro
To functionally assess the role of LASP1 in 
high-risk PCa, we used the LNCaP cell line, which is 
commonly used as an in vitro model for metastasized PCa 
[23]. LNCaP cells were stably transfected with inducible 
shRNA against LASP1 or a control shRNA. Doxycyclin-
induced LASP1 knockdown was confirmed for every 
experiment by Western blot (WB) and showed an average 
silencing of LASP1 of about 50% (Figure 3, lowest panel). 
Proliferation was assessed by cell counting and 
revealed a significant inhibition of cell proliferation up 
to 31% upon LASP1 silencing (Figure 3). Similar results 
were obtained using a CellTiter-Glo® Luminescent assay 
Figure 3: Silencing of LASP1 impairs proliferation 
and migration of prostate cancer cells in vitro. Used 
were non-transfected LNCaP wild type cells (WT) and cells 
stably transfected with control shRNA or shRNA against 
LASP1. Adhesion: After 4 days LASP1 knockdown, cells were 
seeded in 48-well plates and incubated for 7.5h. Adherent cells 
were counted using CellTiterGlo®. Proliferation: Cells were 
seeded in T25 flasks. Knockdown was induced with doxycycline 
(Dox) and cells were counted after 4 days. Migration: After 4 
days LASP1 knockdown, cells were seeded in modified Boyden 
chambers and incubated for 4 h. Migrated cells were fixed, 
stained with crystal violet and absorbance was measured. Bar 
plots represent mean ±SEM; p, Student´s t test, versus control. 
LASP1 knockdown efficiency was controlled by Western blot. 
Actin is shown as loading control.
Table 2: LASP1 and mir-203 expression in BPH, PCa and LNM
Positive
LASP1
nucleus
(≥10%) 
Mean
Nuclear
staining
(range)
Positive 
LASP1
(IRS>5)
Median
IRS
(range)
∆CT
mir-203
(subset)
BPH (n=15) 1 (6.7%) 3.3 (0-13) 1 (6.7%) 2 (0-6) -0.54 ± 0.16   (15)
PCa (n=161) 56 (34.8%) 16.3 (0-95) 39 (24.2%) 3 (0-12) -1.54 ± 0.12 (138)
LNM (n=17) 5 (29.4%) 12.5 (2-50) 2 (11.8%) 4 (1-11) -2.39 ± 0.26   (12)
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(data not shown).
Since LASP1 has been shown to promote cell 
motility and metastasis in other tumor entities [17, 24] 
we analyzed cell migration and adhesion of LNCaP 
cells before and after LASP1 silencing with a modified 
Boyden-chamber and an adhesion assay, respectively. 
We observed a strong reduction in migratory potential by 
39% upon LASP1 silencing but no significant effect on 
adhesion (Figure 3). Taken together, these data provide 
evidence that LASP1 is functionally involved in PCa cell 
proliferation and migration.
Cytosolic and nuclear LASP positivity correlate 
with PSA progress
The prognostic impact of cytosolic and nuclear 
LASP1 immunoreactivity was tested using Kaplan-Meier 
survival analyses. We found a significant correlation 
between PSA recurrence, both, with nuclear LASP1 
Figure 4: Cytosolic and nuclear LASP1 positivity 
correlate with PSA progress A: Kaplan-Meier plot 
displaying patients’ probability for PSA progress stratified 
by cytosolic LASP1 positivity (IRS>5) and negativity 
(IRS<5) B: Kaplan-Meier plot displaying patients’ 
probability for PSA progress stratified by nuclear LASP1 
positivity (NUC≥10%) and negativity (NUC<10%).
Figure 5: mir-203 levels are reduced in prostate cancer 
Reduced mir-203 levels correspond to enhanced LASP1 
protein concentrations. mir-203 expression was analysed by 
qRT-PCR. Relative mir-203 expression values are presented as 
mean ± SEM.
Table 3: Univariate analysis of positive nuclear LASP1 localisation and cytosolic LASP1 staining with clinico-
pathological parameters (n=161)
Parameters
(No. patients)
Positive 
nuclear
LASP1 
(≥10 %)
p-value  Positive
 cytosolic
 LASP1
 (IRS >5)
p-value
Nodal status  
N+  (59)
N-  (102)
16 (27.1%)
40 (39.2%)
0.13 (F)
7 (11.9%)
32 (31.4%)
0.007 (F)
Tumour size  
pT2 (23)
pT3a (44)
pT3b (67)
pT4  (27)
11 (47.8%)
16 (36.4%)
19 (28.4%)
10 (37.0%)
0.33 (M) 
11 (47.8%)
13 (29.5%)
9 (13.4%)
6 (22.2%)
0.012 (M)
Gleason Score       
6  (3)
7  (49)
8  (52)
9  (43)
10  (14)
1 (33.3%)
18 (36.7%)
24 (46.2%)
9 (20.9%)
4 (28.6%)
0.16 (M)
0 (0.0%)
11 (22.4%)
15 (28.8%)
10 (23.3%)
3 (21.4%)
0.84 (M)
Recurrence   (19)
PSA progress (41)
Cancer related death (10)
5 (26.3%)
22 (53.7%)
3 (30%)
0.35 (LT)
0.02 (LT)
0.54 (LT)
6 (31.6%)
16 (34.1%)
5 (50%)
0.54 (LT)
0.04 (LT)
0.10 (LT)
(F) Fisher´s exact test, (M) Mann-Whitney-U-test; (LT) Log-rank test; statistical significance 
is assumed at p<0.05.
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positivity (p=0.017) and with strong LASP1 IRS (p=0.044) 
(Figure 4). These statistical associations were confirmed 
by univariate analysis (Table 3). For cancer related death 
(CRD), we failed to attend significance between cytosolic 
LASP1 levels and this parameter (p=0.1, Table 3). 
However, the overall number of deceased persons (n=10) 
was too low for a statistically robust conclusion on CRD 
(Table 1). Univariate analysis of the data revealed no 
correlation between Gleason score and high cytosolic or 
nuclear LASP1 immunoreactivity (Table 3). In synopsis, 
LASP1 protein expression correlates with PSA progress.
mir-203 levels are reduced in prostate cancer
To investigate the role of mir-203 on LASP1 
expression in PCa, we assessed the mir-203 levels for 
a subset of our cohort described in Table 2 (15 BPH, 
138 high-risk PCa and 12 corresponding PCa/LNM) by 
qRT-PCR and matched the RNA data with the LASP1 
IRS values determined by IHC (Table 2). For PCa a 
significant correlation between high cytosolic LASP1 
protein levels (IRS>5) as well as high nuclear LASP1 
levels (NUC≥10%) and reduced mir-203 expression is 
observed (p=0.002 and p=0.038, respectively). Expression 
levels of mir-203 are significantly reduced from BPH over 
PCa (p=0.006) to LNM (p=0.036) while in return LASP1 
protein levels are increased, supporting the hypothesis of 
LASP1 as a potential marker for aggressive PCa (Figure 
5). 
DISCUSSION
Current clinical staging is unable to accurately 
identify PCa subsets that are prone to progress to 
aggressive lethal disease, even if high Gleason scores 
and elevated PSA levels are used as combined prognostic 
markers [25]. This has contributed to a serious dilemma 
of overtreatment [26]. In the present study we identified 
LASP1 as a potential new prognostic PCa biomarker since 
the protein is significantly overexpressed in PCa compared 
with BPH (p=0.03) in our cohort. Moreover, analysis of 17 
specimens of PCa and their corresponding LNM exhibited 
higher LASP1 levels in metastases, which points to a role 
of LASP1 in tumor progression. In addition, we analyzed 
LASP1 expression in high-risk PCa (Gleason score >8 
and PSA>20 ng/ml) and correlated the immunoreactive 
LASP1 scores with clinicopathological data, which 
yielded a significant correlation between cytosolic and 
nuclear LASP1 levels and PSA progression. Similarly, 
a correlation between nuclear LASP1 localisation and 
poor overall survival is observed in breast cancer [11]. 
For colorectal cancer [17] and medulloblastoma [15] no 
distinct differentiation between cytosolic and nuclear 
LASP1 positivity was performed but patient survival was 
again inversely correlated with global LASP1 expression. 
Unexpectedly, no correlation with clinical progression 
is observed in our study (Table 3). However, on average 
it lasts 8 years from PSA progression to clinically overt 
metastasis [27]. Our median study follow up was 4 
years, which might explain, at least in part, the lack of 
statistically association of LASP1 levels with clinical 
progression in our cohort.
In support of our observations in primary PCa, we 
found a functional role of LASP1 in LNCaP cells. Besides 
a moderate reduction of cell proliferation, we observed 
an impaired migration of LNCaP cells upon inducible 
shRNA-mediated LASP1 knockdown. These in vitro 
results correspond to the in silico predictions derived from 
our GSEA of microarrays of primary PCa, which showed 
an association of LASP1 expression with transcriptional 
signatures involved in locomotory pathways. In analogy, 
reduced cellular migration upon LASP1 knockdown was 
observed in medulloblastoma [15], breast cancer [24], 
and colorectal cancer [17]. Consistently, in several cancer 
entities such as breast cancer [20], bladder cancer [28], 
squamous cell carcinoma [19] and now PCa, increased 
LASP1 protein levels are connected to reduced mir-203 
RNA levels and concomitant enhanced cell proliferation 
and migration. 
Notably, in parallel to our experiments, Erho et 
al. identified LASP1 as one out of 22 marker in a PCa 
genomic classifier (GC) [8]. The study revealed that 60% 
of clinical high-risk patients would be reclassified as low-
risk with a cumulative incidence of metastasis of only 
2.4% at 5 years post radical prostatectomy. Conversely, 
patients with the highest GC score had nearly 10 times 
higher cumulative incidence of metastasis by 5 years. The 
value of this GC in routine clinical practice was assessed 
in two additional studies [29] [30].
In summary, our results suggest that LASP1 
overexpression, most likely mediated by the loss of mir-
203 expression, is involved in progression and metastasis 
of PCa. These data add further functional support for 
LASP1 being part of the new GC set that discriminates 
indolent from more aggressive PCa subtypes.
METHODS
Tissue samples and study population
Patients’ clinicopathologic characteristics are 
summarized in Table 1. 161 archived paraffin-embedded 
tissue samples from human prostate cancer (PCa) with 
confirmed histological diagnoses (radical prostatectomy), 
17 corresponding lymph node metastases (LNM) and 
samples of 15 benign prostatic hyperplasia (BPH) were 
obtained from the Department of Pathology of the 
University of Karlsruhe, Germany [31]. All studies were 
performed with the approval of the Institutional Review 
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board of the Universities of Wuerzburg and Karlsruhe 
and complied with national laws and the declaration of 
Helsinki. Grading of PCa malignancy was evaluated 
according to the Gleason score [32]. Tumor staging 
was conducted according to parameters of the TNM 
classification system [4]. Follow-up was performed every 
3 months for the first 2 years after surgery, every 6 months 
in the following 3 years, and annually thereafter. Clinical 
recurrence is the clinical failure after prostatectomy 
defined either as histologically proven local recurrence 
or distant metastasis confirmed by a CT or bone scan 
that had the date of failure. Biochemical progression/
PSA progression was defined as PSA ≥0.2 ng/ml on 2 
consecutive follow-up visits.
Microarray and gene-set enrichment analyses 
(GSEA)
To compare LASP1 mRNA expression in malignant 
and normal prostate tissue publicly available microarray 
data of primary (n=61) and metastatic PCa (n=25) as well 
as normal prostate tissue (n=18) were retrieved from the 
Gene Expression Omnibus (GEO; accession numbers: 
GSE6604, GSE6605, GSE6606, Affymetrix HG-U95Av2 
arrays). In addition a much larger publicly available gene 
expression data of a study analyzing n=154 individual PCa 
samples was retrieved from the GEO (accession number: 
GSE17951, Affymetrix HG-U133Aplus2.0 microarrays) 
for pathway analyses. Expression data were manually 
revised for their correct annotations and simultaneously 
normalized by Robust Multi-array Average (RMA) [33, 
34] using custom brainarray (v15 and v17 ENTREZG) 
CDF files yielding one optimized probe-set for each gene 
corresponding to the ENTREZ gene ID as described 
elsewhere [35]. To identify pathways and biological 
processes associated with LASP1 overexpression in PCa 
we applied a gene-set enrichment analysis (GSEA) on the 
normalized microarray data [36]. GSEA was performed 
with 1000 permutations using a pre-ranked list composed 
of the log2-transformed fold changes of the median gene 
expression values comparing the top 10 LASP1-high with 
the top 10 LASP1-low PCa samples (Supplemental Table 
1).
Immunohistochemistry
For immunostaining, sections were placed onto 
SuperFrost® slides (Langenbrinck, Emmendingen, 
Germany), dewaxed in xylene, rehydrated in graded 
ethanol and in dH20. For antigen retrieval, sections were 
subjected to heat pre-treatment by boiling in 0.01 M of 
sodium citrate buffer (pH 6.0) for 10 min in a microwave 
oven (750 Watt/sec.). Endogenous peroxidase was blocked 
by incubation in 0.1% hydrogen peroxide in PBS for 5 
min. Slides were then incubated with the polyclonal anti-
LASP1 antibody [37] diluted 1:1000 in “antibody diluent” 
(DAKO, Hamburg, Germany) followed by EnVision/
rabbit detection system (DAKO, Hamburg, Germany). 
All immunohistological samples were evaluated by two 
independent scientists for defining of the percentage of 
LASP1 positive cells and the cytosolic immunoreactivity. 
Scoring of cytosolic LASP1 expression was carried out in 
analogy to the scoring of the hormone receptor Immune 
Reactive Score (IRS), ranging from 0-12 according to 
Remmele et al. and is described in detail for LASP1 in 
breast cancer [12, 38]. For better statistical discrimination, 
samples scored with cytosolic LASP1-IRS <5 were 
classified as LASP1-negative and those with LASP1-
IRS >5 as LASP1-positive. Nuclear LASP1 positivity: 
Nuclear LASP1 positivity was scored by determining 
the percentage of positive nuclei regardless of cytosolic 
LASP1 immunoreactivity. Samples were considered as 
nuclear-positive if 10% or more cells showed nuclear 
LASP1 staining.
Cell lines and culture conditions
PCa cell line LNCaP derived from a lymph node 
metastasis was purchased from American Type Culture 
Collection (ATCC, Manassas, USA). Cells were grown 
in plastic cell culture flasks at 37ºC under 5% CO2 
atmosphere in RPMI 1640 medium (Life Technologies, 
Darmstadt, Germany) containing 10% heat-inactivated 
fetal bovine serum (FBS), 1% penicillin/streptomycin, 1% 
non-essential amino acids and 1% pyruvate (all Invitrogen, 
Darmstadt, Germany). Mycoplasma contamination was 
ruled out by PCR.
mir-203 - qRT-PCR
Total RNA was extracted from PCa, LNM and 
BPH tissues with Total RNA Extraction Kit (Life 
Technologies). The RNA concentration was determined 
with a Bioanalyser (Biorad, Munich, Germany). cDNA 
was synthesized according to the TaqMan miR Assay 
protocol (Life Technologies). Mature mir expression was 
quantified in tissue samples with TaqManR mir assay 
kits and an Applied Biosystems 7900 HT system. We 
followed the protocol provided in the manufacturer´s 
instruction (Applied Biosystems, Foster City, CA, USA). 
The expression of RNU6B was used for normalization. 
Relative mir expression was calculated with the ΔCt-
method (ΔCt sample = Ct RNU6B - Ct sample). 
Calculations were carried out assuming equal RNA-
concentrations and complete efficacy of qRT-PCR.
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RNA interference 
For generation of an inducible LASP1 
knockdown, LNCaP cells were infected with lentivirus 
(MOI: 1:10) containing a pTRIPZ vector with 
either a short hairpin RNA (shRNA) against LASP1 
(clone V2THS-64686 mature antisense sequence 
5’-GGCAAGTGGAATATCTTATAT-3’, Thermo 
Scientific) or respective non-targeting control shRNA. 
Successfully transduced LNCaP were selected in 0.5 µg/
ml puromycin (Invitrogen). Knockdown efficiency upon 
doxycycline-treatment (0.5µg/ml) was confirmed by WB.
Lentivirus production: 5.5x106 HEK293T cells 
were seeded into a 100 mm cell culture dish coated with 
0.01% poly-L-lysine (Sigma-Aldrich, Deisenhofen, 
Germany) one day prior to transfection and cultured in 
DMEM (Invitrogen) supplemented with 10% FBS, 1% 
penicillin/streptomycin (both Invitrogen). Arrest-InTM 
(Thermo Scientific) was used as transfection reagent. 
DNA/Arrest-In™ complexes were formed by mixing 9 
µg of the particular pTRIPZ vector DNA, with 28.5 µg of 
optimized packaging plasmid mix (pTLA1-Pak, pTLA1-
Enz, pTLA1-Env, pTLA1-Rev and pTLA1-TOFF, all 
Open Biosystems, Thermo Scientific) in 1ml DMEM with 
187.5 µg Arrest-InTM diluted in 1ml DMEM. Supernatant 
was harvested 48h and 72h after transfection and lentiviral 
particles were isolated by filtration and subsequent 
ultracentrifugation.
Western blot (WB)
Cells were lysed in Laemmli-buffer containing 10% 
β-mercaptoethanol (Sigma-Aldrich). Equal amounts of 
cells were resolved by 10% SDS-PAGE. After blotting on 
a nitrocellulose membrane (Schleicher&Schuell, Dassel, 
Germany) the membrane was blocked with 3% nonfat dry 
milk (Biorad) in TBS-T buffer (10 mM TRIS, 150 mM 
NaCl, 0.1% (w/v) Tween, pH 7.5). Then the membrane 
was incubated with a self-generated primary antibody 
against LASP1 [35] diluted 1:8000 and anti-β-Actin by 
Santa Cruz (Santa Cruz, CA, USA) diluted 1:2000. Finally 
the membrane was washed with TBS-T and incubated 
with the secondary antibody goat-anti-rabbit horseradish 
peroxidase-coupled and diluted 1:5000 (Biorad). The 
amount of detected protein was visualized by enhanced 
chemiluminescence (Amersham Biosciences, Freiburg, 
Germany) and autoradiography. Quantification of 
autoradiography signals was carried out by densitometry 
using the ImageJ software (NIH, Bethesda, USA).
Proliferation assays
Non-transduced LNCaP cells and cells stable 
transduced with control shRNA or shRNA against LASP1 
were seeded in 48-well plates. Per well 1x104 cells were 
seeded. After 24 h, medium was replaced by medium +/- 
doxycycline (0.5 µg/ml). 96h after knockdown induction, 
cells were counted with CellTiter-Glo ® Luminescent 
Cell Viability Assay (Promega) following manufacturer´s 
instruction. Assays were performed in 5 independent 
experiments, each with 6 replicates. In addition, the 
experiment was performed in T25 flasks and cells were 
counted with Neubauer chamber. Knockdown of LASP1 
was confirmed in each experiment by WB.
Adhesion assay 
To assess cell adhesion non transduced LNCaP cells 
and cells stable transduced with control shRNA or shRNA 
against LASP1 were grown for 96h in media (as described 
previously) +/- doxycycline (0.5µg/ml). Cells were seeded 
in 48-well plates, per well 4x104 cells in 100µl media. 
Cells were allowed to attach for 7.5 h at 37°C (ca. 50 % 
adhesion of control cells). In 5 of 8 wells, non-adherent 
cells were removed by gentle washing with PBS and wells 
were refilled with 100 µl medium. Wells with non washed-
off cells served as 100 % value of seeded cells. Cells were 
counted with CellTiter-Glo ® Luminescent Cell Viability 
Assay (Promega) following manufacturer´s instruction. 
Assays were performed in 6 independent experiments, 
(each with 5 replicates). Knockdown of LASP1 was 
comfirmed in each experiment by WB.
Migration assay
Cellular migration was assessed by a modified 
Boyden chamber assay (transwell chambers, Corning 
Star, Cambridge, MA, USA). Cells were serum-starved 
overnight, trypsinized, adjusted for viability, counted, and 
re-suspended in serum-free medium to a concentration of 
1x106 cells/ml. Before the experiment, the lower surface 
of the filter membrane (8 µM pore size) was coated for 
15 min with 100 µl fibronectin solution (5 µg/ml; Sigma-
Aldrich) as a chemo-attractant. The inner filter chambers 
were coated with 100 µl 10% FBS in RPMI medium for 
30 min. 100 µl cell suspension was placed in the upper 
filter chambers. The chambers were placed in 24-well 
plates and cultured in 500 µl RPMI medium with 10% 
FBS for 4 h at 37°C to allow the cells to migrate through 
the porous membrane. Non-migrated cells from the top 
surface were removed using a cotton swab. Migrated cells 
at the lower surface of the membranes were stained in 200 
µl 1% (w/v) crystal violet in 2% ethanol in a 24-well plate 
for 30 sec and rinsed twice afterwards in distilled water. 
Cell-associated crystal violet was extracted by incubating 
the membrane in 200 µl 10% acetic acid for 20 min and 
measured at 595 nm absorbance using a plate reader 
(Molecular Devices, Crawley, UK). Four independent 
experiments, each with 6 replicates, were performed
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